Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.

Flurina AM Saner; Kazuaki Takahashi; Timothy Budden; Ahwan Pandey; Dinuka Ariyaratne; Tibor A Zwimpfer; Nicola S Meagher; Sian Fereday; Laura Twomey; Kathleen I Pishas; Therese Hoang; Adelyn Bolithon; Nadia Traficante; Kathryn Alsop; Elizabeth L Christie; Eun-Young Kang; Gregg S Nelson; Prafull Ghatage; Cheng-Han Lee; Marjorie J Riggan; Jennifer Alsop; Matthias W Beckmann; Jessica Boros; Alison H Brand; Angela Brooks-Wilson; Michael E Carney; Penny Coulson; Madeleine Courtney-Brooks; Kara L Cushing-Haugen; Cezary Cybulski; Mona A El-Bahrawy; Esther Elishaev; Ramona Erber; Simon A Gayther; Aleksandra Gentry-Maharaj; C Blake Gilks; Paul R Harnett; Holly R Harris; Arndt Hartmann; Alexander Hein; Joy Hendley; AOCS Group; Brenda Y Hernandez; Anna Jakubowska; Mercedes Jimenez-Linan; Michael E Jones; Scott H Kaufmann; Catherine J Kennedy; Tomasz Kluz; Jennifer M Koziak; Björg Kristjansdottir; Nhu D Le; Marcin Lener; Jenny Lester; Jan Lubiński; Constantina Mateoiu; Sandra Orsulic; Matthias Ruebner; Minouk J Schoemaker; Mitul Shah; Raghwa Sharma; Mark E Sherman; Yurii B Shvetsov; Naveena Singh; T Rinda Soong; Helen Steed; Paniti Sukumvanich; Aline Talhouk; Sarah E Taylor; Robert A Vierkant; Chen Wang; Martin Widschwendter; Lynne R Wilkens; Stacey J Winham; Michael S Anglesio; Andrew Berchuck; James D Brenton; Ian Campbell; Linda S Cook; Jennifer A Doherty; Peter A Fasching; Renée T Fortner; Marc T Goodman; Jacek Gronwald; David G Huntsman; Beth Y Karlan; Linda E Kelemen; Usha Menon; Francesmary Modugno; Paul DP Pharoah; Joellen M Schildkraut; Karin Sundfeldt; Anthony J Swerdlow; Ellen L Goode; Anna DeFazio; Martin Köbel; Susan J Ramus; David DL Bowtell; Dale W Garsed

Journal article

Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.

Flurina AM Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A Zwimpfer, Nicola S Meagher, Sian Fereday, Laura Twomey, Kathleen I Pishas, Therese Hoang, Adelyn Bolithon, Nadia Traficante, Kathryn Alsop, Elizabeth L Christie, Eun-Young Kang, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan Show all

medRxiv | Published : 2023

DOI: 10.1101/2023.11.09.23298321

Abstract

BACKGROUND: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in homologous recombination DNA repair genes including BRCA1 and BRCA2 (BRCA). We examined whether tumour expression of RB1 was associated with survival across ovarian cancer histotypes (HGSC, endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous carcinoma (LGSC)), and how co-occurrence of germline BRCA pathogenic variants and RB1 loss influences long-term survival in a large series of HGSC. PATIENTS AND METHODS: RB1 protein expression patterns were classified by immunohistochemistry in epithelial ovarian ca..

View full abstract